Is Kwality Pharmaceuticals Ltd (KPL) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kwality Pharmaceuticals Ltd is a average quality company .

Is Kwality Pharmaceuticals Ltd (KPL) undervalued or overvalued?

The key valuation ratios of Kwality Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Kwality Pharmaceuticals Ltd (KPL) share price return in the past 10 years?

Data is not available for this company

Is Kwality Pharmaceuticals Ltd (KPL) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kwality Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Kwality Pharmaceuticals Ltd (KPL)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kwality Pharmaceuticals Ltd (KPL) on 04-May-2026 16:59:59 at 16:59 is 1657.00.

What is the P/E ratio of Kwality Pharmaceuticals?

The latest standalone P/E ratio of Kwality Pharmaceuticals as of 04-May-2026 is 30.40.

What is the P/B ratio of Kwality Pharmaceuticals Ltd (KPL)?

The latest standalone P/B ratio of Kwality Pharmaceuticals Ltd (KPL) as of 04-May-2026 is 5.60.

What is the 52-week high and low of Kwality Pharmaceuticals Ltd (KPL)?

The 52-week high of Kwality Pharmaceuticals Ltd (KPL) is Rs. 1782.00 and the 52-week low is Rs. 666.00.

Kwality Pharmaceuticals Ltd (KPL) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kwality Pharmaceuticals Ltd (KPL)
Brand: Kwality Pharmaceuticals

Kwality Pharmaceuticals Ltd (KPL) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kwality Pharmaceuticals Ltd (KPL)

BSE: 539997 NSE: KPL

Key Metrics

Market Cap

₹1,719 Cr.

P/E Ratio

30.40

Price to Book (P/B)

5.60

Price to Sales (P/S)

3.72

EV/EBITDA

16.64

Return on Capital Employed (ROCE)

18.30%

Current Price

₹1,657

Return on Equity (ROE)

16.28%

Return on Assets (ROA)

9.42%

Operating Profit Margin

21.7%

Net Profit Margin

10.78%

Gross Profit Margin

19.6%

Book Value per Share

₹296

Sales Growth (YoY)

20.52%

Sales Growth (3 Years)

-6.72%

Operating Profit Growth (1 Year)

20.73%

Operating Profit Growth (3 Years)

-22.34%

Net Profit Growth (1 Year)

66.35%

52-Week Low / High

₹666 / 1,782

Net Profit Growth (3 Years)

-30.74%

Dividend Yield

0.00%

Promoter Holding

54.87%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Kwality Pharmaceuticals Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 69.63% based on the current price.

Q.1 Revenue growth of Kwality Pharmaceuticals Ltd?

Kwality Pharmaceuticals Ltd revenue growth is 20.5% for FY-2025, which is below its 5-year CAGR of 21.7%, indicating slower growth.

Q.1 Which industry/sub-sector does Kwality Pharmaceuticals Ltd belong to?

Kwality Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Kwality Pharmaceuticals Ltd?

Promoters hold 54.87% of the Kwality Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Kwality Pharmaceuticals Ltd vs industry peers?

Kwality Pharmaceuticals Ltd revenue CAGR is 21.70%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

DeciZen - make an informed investing decision on Kwality Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation ⓘ

3. Price Trend

Kwality Pharmaceuticals stock performance

Key Ratios

Is Kwality Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	14%	19.5%	19.4%	21.5%	18.5%	26.5%	97.2%	12.3%	13.6%	18.3%	-
Value Creation Index ⓘ	-0	0.4	0.4	0.5	0.3	0.9	5.9	-0.1	0.0	0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	75.9	95.3	137	165	139	262	456	251	307	370	462
Sales YoY Gr.	-	25.6%	43.6%	20.7%	-16%	88.6%	74.4%	-45%	22.4%	20.5%	-
Adj EPS ⓘ	2.1	3.7	4.5	7.3	8	14.6	114.6	29	27.9	38.4	54.5
YoY Gr.	-	73.8%	19.9%	63%	9.4%	83.9%	683.7%	-74.7%	-3.8%	37.4%	-
BVPS (₹) ⓘ	21.6	24.6	29.2	36.5	44.6	59.5	175.2	193.9	217	255.4	296
Adj Net Profit ⓘ	2.2	3.9	4.6	7.5	8.3	15.2	119	30.1	29	39.8	57
Cash Flow from Ops. ⓘ	-2.6	4	-0.1	13	5.6	26.4	59.2	42.2	43.4	52.8	-
Debt/CF from Ops. ⓘ	-5	4.7	-275.3	2.2	6.2	1.6	0.9	2.1	2.3	2.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	19.3%	21.7%	-6.7%	20.5%
Adj EPS ⓘ	37.8%	37%	-30.6%	37.4%
BVPSⓘ	31.6%	41.8%	13.4%	17.7%
Share Price	-	72.2%	71.6%	130.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	10.2	15.8	16.1	21.6	19.2	27.7	97	15.7	13.5	16.2	19.8
Op. Profit Mgn % ⓘ	7.6	9.6	8.4	9.2	10.2	11.2	37.7	24.3	21.7	21.7	22.8
Net Profit Mgn % ⓘ	2.8	4.1	3.4	4.6	6	5.8	26.1	12	9.4	10.8	12.3
Debt to Equity ⓘ	0.6	0.7	0.9	0.7	0.8	0.7	0.3	0.5	0.4	0.4	-
Working Cap Days ⓘ	139	157	155	154	203	126	129	319	276	265	120
Cash Conv. Cycle ⓘ	69	78	69	63	78	36	33	141	151	151	53

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	54.5	54.5
TTM Sales (₹ Cr.)	462	462
BVPS (₹) ⓘ	296	294.2
Reserves (₹ Cr.) ⓘ	297	295
P/BV ⓘ	5.60	5.63
PE ⓘ	30.40	30.41

From the Market
52 Week Low / High (₹)	666.00 / 1782.00
All Time Low / High (₹)	20.43 / 1782.00
Market Cap (₹ Cr.)	1,719
Equity (₹ Cr.)	10.4
Face Value (₹)	10
Industry PE ⓘ	43.8

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kwality Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	76	95	137	165	139	262	456	251	307	370
Operating Expenses ⓘ +	70	87	125	150	125	232	284	190	241	290
Manufacturing Costs	4	5	8	7	8	13	79	63	93	95
Material Costs	58	70	102	119	87	166	142	69	90	116
Employee Cost	2	4	5	8	11	14	19	28	30	41
Other Costs ⓘ	6	8	11	16	19	39	44	30	28	38
Operating Profit ⓘ	5	9	11	15	14	29	172	61	67	80
Operating Profit Margin (%)	7.1%	9.0%	8.4%	9.2%	10.2%	11.2%	37.6%	24.3%	21.7%	21.7%
Other Income ⓘ +	1	2	1	1	4	2	4	3	2	2
Exceptional Items ⓘ	0	0	0	0	0	0	0	-17	-7	0
Interest ⓘ	1	2	2	2	3	3	3	7	10	10
Depreciation ⓘ	2	2	3	3	4	6	11	15	20	18
Profit Before Tax ⓘ	3	6	8	11	11	22	162	26	31	54
Tax ⓘ	1	2	3	3	3	6	42	6	7	14
Profit After Tax	2	3	5	8	8	15	120	19	24	40
PAT Margin (%)	2.5%	3.6%	3.4%	4.6%	6.1%	5.9%	26.3%	7.8%	7.8%	10.8%
Adjusted EPS (₹)	1.9	3.3	4.5	7.3	8.1	14.9	115.7	18.8	23.1	38.4
Dividend Payout Ratio (%)	0%	9.10%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	23	26	31	39	47	63	183	202	226	266
Share Capital ⓘ	5	5	10	10	10	10	10	10	10	10
Reserves ⓘ	18	21	21	28	37	52	172	192	216	255
Debt +	12	18	25	26	31	35	43	78	86	98
Long Term Debt	3	3	4	7	10	18	20	27	20	15
Short Term Debt	10	15	21	19	21	16	23	51	66	83
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	10	13	22	17	23	26	35	35	44	56
Others Liabilities ⓘ	8	15	19	26	33	45	82	41	42	29
Total Liabilities ⓘ	52	72	98	107	134	169	343	357	398	449
Fixed Assets
Net Fixed Assets ⓘ +	11	14	15	22	42	56	91	120	138	144
Gross Block	21	27	31	40	61	81	127	169	205	230
Accumulated Depreciation	10	12	15	18	20	25	36	49	67	85
CWIP ⓘ	0	1	4	6	0	3	12	14	0	0
Investments ⓘ	5	7	9	8	8	9	4	4	4	4
Inventories	9	14	15	11	22	17	53	86	78	83
Trade Receivables	20	23	37	39	30	38	71	73	116	156
Cash Equivalents	1	2	1	0	1	5	11	6	5	14
Others Assets ⓘ	7	11	17	20	31	41	101	53	56	47
Total Assets ⓘ	52	72	98	107	134	169	343	357	398	449

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-3	4	-0	13	6	26	59	42	43	53
PBT ⓘ	3	6	8	11	11	22	162	26	31	54
Adjustment ⓘ	3	4	5	5	6	9	14	21	37	28
Changes in Working Capital ⓘ	-7	-4	-9	1	-9	2	-75	2	-23	-14
Tax Paid ⓘ	-1	-2	-3	-3	-3	-6	-41	-6	-1	-16
Cash Flow From Investing Activity ⓘ +	-2	-7	-6	-12	-17	-23	-63	-48	-26	-28
Capex	-2	-7	-6	-12	-18	-23	-55	-46	-26	-25
Net Investments	-0	-1	-0	-1	1	-0	-0	0	0	0
Others ⓘ	0	0	1	1	0	0	-8	-3	-1	-4
Cash Flow From Financing Activity ⓘ +	5	5	5	-2	12	1	6	1	-17	-14
Net Proceeds from Shares ⓘ	2	1	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	2	1	1	3	3	10	9	7	-7	-5
Interest Paid ⓘ	-1	-2	-2	-2	-2	-3	-3	-6	-10	-10
Dividend Paid ⓘ	0	-0	0	0	0	0	0	0	0	0
Others ⓘ	3	5	6	-3	12	-7	0	0	0	0
Net Cash Flow ⓘ	0	1	-1	-1	1	4	2	-5	-0	10

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	9.3	14.58	16.76	22.17	20.05	28.55	98.61	10.17	11.25	16.28
ROCE (%)	13.98	19.51	19.37	21.47	18.53	26.51	97.19	12.28	13.62	18.3
Asset Turnover Ratio	1.68	1.53	1.61	1.61	1.15	1.72	1.78	0.72	0.81	0.87
PAT to CFO Conversion(x)	-1.5	1.33	-0	1.63	0.75	1.73	0.49	2.21	1.79	1.33
Working Capital Days
Receivable Days	69.40	81.40	79.80	83.90	90.90	47.50	43.40	104.70	112.50	134
Inventory Days	36.30	42.80	38.20	28.90	44.30	27.80	28.30	101.60	97.90	79.80
Payable Days	43.20	58.70	62.20	59.60	83.90	54.20	78.10	183.20	161.90	157.20

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kwality Pharmaceuticals Ltd FAQs

The current trading price of Kwality Pharma on 04-May-2026 16:59 is ₹1,657.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-May-2026 the market cap of Kwality Pharma stood at ₹1,719.3 Cr

The latest P/E ratio of Kwality Pharma as of 03-May-2026 is 30.40.

The latest P/B ratio of Kwality Pharma as of 03-May-2026 is 5.60.

The 52-week high of Kwality Pharma is ₹1,782 and the 52-week low is ₹666.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kwality Pharma is ₹462 ( Cr.) .

About Kwality Pharmaceuticals Ltd

The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.

The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization).

Milestones

1983: Incorporation of the company on May 04, 1983.
2007: Received ISO Certification.
2008: Commencement of new manufacturing unit at Jassur in Himachal Pradesh.
2009: Received status of Star Export House Certificate.
2012: Turnover increased by 75%.
2013: Incorporation of Subsidiary Company in Africa.
2014: Received WHO certification.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kwality Pharmaceuticals Ltd (KPL) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kwality Pharma Share Price